Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing

References

• Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther.87(1), 52–56 (2010).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics12(2), 101–109 (2002).
   PubMedGoogle Scholar
• Kirchheiner J, Brockmoller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther.71(4), 286–296 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTS study. Diabetes56(8), 2178–2182 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes58(6), 1434–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Pearson ER, Antcliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med.350(18), 1838–1849 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Flechtner I, Njolstad PR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med.355(5), 467–477 (2006).
   PubMed Web of Science ®Google Scholar
• Meigs JB, Shrader P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of Type 2 diabetes. N. Engl. J. Med.359(21), 2208–2219 (2008).
   PubMed Web of Science ®Google Scholar
• Grant RW, Moore AF, Florez JC. Genetic architecture of Type 2 diabetes: recent progress and clinical implications. Diabetes Care32(6), 1107–1114 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care32(1), 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med.358(10), 999–1008 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G et al.HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6), 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost–effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS22(15), 2025–2033 (2008).
   PubMed Web of Science ®Google Scholar
• Park L, Wexler D. Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. Curr. Opin. Lipidol.21(1), 8–14 (2010).
   Google Scholar
• Within-trial cost–effectiveness of lifestyle intervention or metformin for the primary prevention of Type 2 diabetes. Diabetes Care26(9), 2518–2523 (2003).
   PubMed Web of Science ®Google Scholar
• Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in Type 2 diabetes: a patient and physician survey. Diabetologia52(11), 2299–2305 (2009).
   PubMed Web of Science ®Google Scholar
• Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA298(14), 1682–1684 (2007).
   PubMed Web of Science ®Google Scholar
• Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA299(11), 1320–1334 (2008).
   PubMed Web of Science ®Google Scholar
• Joy MS, Dornbrook-Lavender K, Blaisdell J et al.CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur. J. Clin. Pharmacol.65(9), 947–953 (2009).
   Google Scholar
• Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol.5(6), 607–620 (2009).
   PubMed Web of Science ®Google Scholar
• Gold LS, De Roos AJ, Brown EE et al. Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol.33(3–4), 276–280 (2009).
   PubMed Web of Science ®Google Scholar